Targeting cancer
with customized T cells
Reprogramming
the immune attack
Leveraging T cell
receptor-driven activation

Triumvira Immunologics is a biotechnology company developing a novel platform for engineering T cells to attack cancers.
More
T Cell-Antigen Couplers (TACs) are designed to provide a more regulated activation of T cells by using the T cell’s natural activation pathways.
More
With an initial focus on hematologic malignancies, we are aiming to develop a broad pipeline in solid tumors as well.
More
Explore our news and press releases that detail the progress of Triumvira's research efforts, pipeline and lead direction.
More

Using TAC Technology to Attack Cancer Cells

At Triumvira Immunologics, we are reprogramming the immune system to attack cancer cells. In order to do this, we use genetic engineering to redirect T cells, an important component of the immune system, to recognize proteins found on the surface of cancer cells.  We use T cells taken from a patient, engineer them to express our T cell-Antigen Coupler (TAC), then expand them and then administer the modified cells back to patients, where they will find the cancer cells and kill them. Triumvira’s TACs are a completely novel and innovative approach to reprogramming T cells, which we believe offer important advantages over the approach taken by other companies.

News & Press Releases

04/25/2017
TRIUMVIRA TO PRESENT CORPORATE UPDATE AT THE BLOOM BURTON & CO. HEALTHCARE INVESTOR CONFERENCE

Triumvira Immunologics Inc. today announced that its President and Chief Executive Officer Tony Fiorino, MD, PhD, will present a corporate update at the Bloom Burton & Co. Healthcare Investor Conference taking place May 1 and 2, 2017 at the Sheraton Centre Toronto Hotel, Toronto, Canada.

Read More
04/03/2017
TRIUMVIRA TO PRESENT CORPORATE UPDATE AT THE 24TH ANNUAL FUTURE LEADERS IN THE BIOTECH INDUSTRY

Triumvira Immunologics Inc. today announced that its President and Chief Executive Officer Tony Fiorino, MD, PhD, will present a corporate update at the 24th Annual Future Leaders in the Biotech Industry.

Read More
11/10/2016
NEW CD19 AND BCMA DATA TO BE PRESENTED AT THE SOCIETY FOR IMMUNOTHERAPY OF CANCER ANNUAL MEETING

Triumvira Immunologics today announced that new data on the TAC platform will be presented Friday, November 11 at the 31st Annual Meeting of the Society for Immunotherapy of Cancer (SITC) in National Harbor, Maryland.

Read More
06/28/2016
SOLID TUMOR PRECLINICAL DATA FOR HER2 TAC-T CELLS PRESENTED AT SUMMIT FOR CANCER IMMUNOTHERAPY

Triumvira Immunologics Inc. presented a talk entitled “T Cell-Antigen Coupler Engineered T Cells Demonstrate Efficacy Against Solid Tumors” during at the Summit for Cancer Immunotherapy in Halifax, Nova Scotia.

Read More